Prenatal Test for Fetal Aneuploidy Detection

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ariosa Diagnostics, Inc
ClinicalTrials.gov Identifier:
NCT01256606
First received: November 22, 2010
Last updated: January 8, 2013
Last verified: January 2013

November 22, 2010
January 8, 2013
August 2010
November 2011   (final data collection date for primary outcome measure)
Comparison of blood test to results from chorionic villus sampling or amniocentesis for fetal aneuploidy detection [ Time Frame: 24 months ] [ Designated as safety issue: No ]
Circulating genomic material from maternal blood will be quantified using biochemical techniques to determine the presence of fetal aneuploidy. The results obtained from analysis of circulating genomic material will be compared to the karyotype results from chorionic villus sampling or amniocentesis.
Same as current
Complete list of historical versions of study NCT01256606 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Prenatal Test for Fetal Aneuploidy Detection
Investigational Study of a Prenatal Diagnostic Test for Fetal Aneuploidy

The purpose of this study is to develop and evaluate a blood test for pregnant women for detection of fetal aneuploidy.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Pregnant women planning to undergo chorionic villus sampling or amniocentesis for fetal genetic evaluation

  • Aneuploidy
  • Trisomy 21
Not Provided
  • Positive for fetal aneuploidy
  • Negative for fetal aneuploidy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4000
November 2011
November 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject is 18yrs or older
  • Subject has a singleton pregnancy
  • Subject is planning to undergo chorionic villus sampling (CVS) and/or amniocentesis with current pregnancy
  • Subject is able to provide consent

Exclusion Criteria:

  • Subject is pregnant with more than one fetus
  • Subject (mother) has known aneuploidy
  • Subject has active malignancy requiring major surgery or systemic chemotherapy or has a history of metastatic cancer.
  • Subject has already undergone CVS or amniocentesis during current pregnancy prior to study enrollment.
Female
18 Years to 60 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01256606
TT001
No
Ariosa Diagnostics, Inc
Ariosa Diagnostics, Inc
Not Provided
Study Director: Ken Song, MD Ariosa Diagnostics
Ariosa Diagnostics, Inc
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP